Philip C. Mack, Ph.D.

Clinical/Research Interests

Dr. Mack conducts molecular biology and molecular pharmacology studies for the UC Davis Cancer Center, the California Cancer Consortium, and the Southwest Oncology Group. For the past twelve years, Dr. Mack has conducted basic and translational research, with an emphasis on lung cancer. His investigations include molecular and cellular effects of novel anticancer agents in lung cancer models. Dr. Mack is Director of the UC Davis Cancer Center Molecular Pharmacology shared resource, Director of Basic Sciences for the California Cancer Consortium and Associate Director of the Southwest Oncology Group Lung Translational Medicine Committee.

Title:

Associate Adjunct Professor, Co-leader Molecular Pharmacology

Specialty:

Hematology and Oncology, Cancer, Molecular Biology/Medicine

Education:

UC Davis
Davis, California
Ph.D. 1997

UC Santa Cruz
Santa Cruz, California
B.A. 1991

Professional Memberships:

American Association for Cancer Research
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Southwest Oncology Group

Honors and Awards:

University of California Academic Federation Travel Award, 2006, 2008
University of California Academic Federation Travel Award, 2003, 2004
Helen and Christine Landgraf Memorial Research Fund Award, 2002
American Cancer Society, California Division, Clinical Research Fellowship, 1999-2001

Select Recent Publications:

Chinn DC, Holland WS, Yoon JM, Zwerdling T, Mack PC. Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer. 2011 Jul 27. doi: 10.1002/pbc.23270.

Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2011 Jul 25. doi: 10.1002/ijc.26303.

Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2011 Jul 21.

Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN Jr. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2011 Jun 5.

Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 1;28(31):4747-54.

Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010. Epub 2010 Oct 4.

2009 McCall JL, Burich RA, Mack Pc. GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines. Leuk Res, 2009 Apr 24.

2009 Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi 0, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japan-USA common arm analysis of pad itaxelcarboplatin in advanced non-small cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of Clin Oncol. 27:3540-3546.

2009 Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr., Davies AM, Gandara DR. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2008 Oct 10;26(29):4771-6. Epub 2008 Sep 8.

2008 Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr., Franklin WA, Le Q-T, Crowley JJ and Gandara DR. Lower Osteopontin Plasma Levels are Associated with Superior Outcomes Following Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: Southwest Oncology Group Trial S0003. Journal of Clinical Oncology, 26(29):4771-4776, 2008.